Investors & Media Press Releases

Axovant Sciences to Present at Upcoming Investor Conferences


BASEL, Switzerland, Jan. 25, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:

  • February 16 at 1:30 p.m. EST at the Leerink Partners 6th Annual Global Healthcare Conference
  • February 22 at 11:30 a.m. EST at the RBC Capital Markets 2017 Healthcare Conference

A simultaneous webcast will be available for each conference in the Investors section of Axovant's website at A replay will be available for 30 days following each conference.

About Axovant Sciences
Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.

To view the original version on PR Newswire, visit:

SOURCE Axovant Sciences

Jonathan Neely
Head, Investor Relations and Corporate Communications
Axovant Sciences, Inc.
(212) 634-9744